Business Context and Reporting Period
This Form 8-K, filed by Graybug Vision, Inc. (the Registrant) on February 16, 2023, reports events occurring on February 10, 2023. The filing details a material definitive agreement between Graybug and CalciMedica, Inc. (CalciMedica) in connection with their proposed merger. Graybug is an emerging growth company listed on the Nasdaq Global Market under the symbol "GRAY."
Key Financial Metrics and Agreements
- Loan Facility: Graybug entered into a Note Purchase Agreement to provide short-term loans to CalciMedica up to an aggregate principal amount of $2.0 million.
- Initial Disbursement: An initial loan of $500,000 was made on February 10, 2023.
- Interest Rate: Loans bear simple interest at 7.5% per annum, payable in arrears.
- Remaining Availability: The remaining $1.5 million is subject to certain conditions and restrictions on use.
- Merger Accounting: An amendment to the Merger Agreement stipulates that outstanding principal and accrued interest from these loans will be included in the calculation of Graybug's net cash at the closing of the Merger.
Note: This filing does not provide standalone revenue, profit, cash flow, or margin data for either company. It focuses solely on the transaction terms.
Material Changes and Transaction Purpose
The primary material change is the entry into the Note Purchase Agreement and the First Amendment to the Merger Agreement. CalciMedica requested the loan to secure sufficient cash to fund its operations until the anticipated closing date of the Merger. The amendment ensures that the debt incurred for this purpose is treated as cash on hand for the merger closing calculation.
Guidance, Risks, and Contingencies
The filing contains forward-looking statements regarding the timing and completion of the Merger and CalciMedica's ability to satisfy borrowing conditions. Key risks and contingencies include:
- Merger Completion: Uncertainty regarding the ability to consummate the Merger in a timely manner or at all.
- Closing Conditions: Risks related to stockholder approval, continued Nasdaq listing, and potential delays.
- Financial Forecasting: CalciMedica's ability to accurately forecast cash needs and the impact of global financial market fluctuations.
- Termination Risks: Events that could lead to the termination of the Merger Agreement and CalciMedica's subsequent ability to repay the loans.
- Legal Proceedings: Potential litigation related to the Merger Agreement.
Investor Verification Checklist
- Verify the status of the Definitive Proxy Statement (Schedule 14A) for details on the Merger terms and voting requirements.
- Review the Note Purchase Agreement (Exhibit 99.1) for specific conditions restricting the use of the remaining $1.5 million.
- Confirm the First Amendment to the Merger Agreement (Exhibit 2.1) to understand how the loan impacts the net cash calculation at closing.
- Monitor CalciMedica's operational cash burn rate to assess the necessity of drawing down the full $2.0 million facility.
- Check for any updates on Nasdaq listing compliance for Graybug, as this is a stated closing condition.